Long-term Perspective with Nivolumab plus Ipilimumab

被引：0

作者：

不详

机构：

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The combination of nivolumab + ipilimumab can now be used in 6 entities [1, 2]. The long-term data from the respective approval studies show unanimously that some of those affected can benefit from the treatment in the long term [3-8]. The combination therefore represents a therapy concept with a long-term perspective that combines the chance of long-term survival with sustained tumor control. The durability is explained here using the example of the RCC [1-3].

引用

页数：1

共 50 条

[21] HEALTH CARE COST COMPARISON ANALYSIS OF NIVOLUMAB plus IPILIMUMAB REGIMEN, NIVOLUMAB MONOTHERAPY, AND IPILIMUMAB MONOTHERAPY UTILIZING CLINICAL TRIAL DATA: A EUROPEAN PERSPECTIVE
Potluri, R.
Sabater, J.
Bhandari, H.
Ranjan, S.
Kotapati, S.
VALUE IN HEALTH, 2016, 19 (03) : A144 - A144
[22] Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
Borghaei, H.
Ciuleanu, T. -E.
Lee, J. -S
Pluzanski, A.
Caro, R. Bernabe
Gutierrez, M.
Ohe, Y.
Nishio, M.
Goldman, J.
Ready, N.
Spigel, D. R.
Ramalingam, S. S.
Paz-Ares, L. G.
Gainor, J. F.
Ahmed, S.
Reck, M.
Maio, M.
O'Byrne, K. J.
Memaj, A.
Nathan, F.
Tran, P.
Hellmann, M. D.
Brahmer, J. R.
ANNALS OF ONCOLOGY, 2023, 34 (02) : 173 - 185
[23] BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer
Fischer, R. N.
George, J.
Schaefer, S.
Scheel, A.
Schloesser, H.
Vehreschild, M.
von Bergwelt-Baildon, M.
Nogova, L.
Abdulla, D. S. Y.
Michels, S.
Riedel, R.
Scheffler, M.
Brossart, P.
Engel-Riedel, W.
Griesinger, F.
Grohe, C.
Kambartel, K.
Kern, J.
Kopp, H-G
Neukirchen, J.
Overbeck, T. R.
Panse, J.
Sebastian, M.
Serke, M.
Wiewrodt, R.
Buettner, R.
Thomas, R.
Wolf, J.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 270 - 271
[24] Gauging the Long-Term Benefits of Ipilimumab in Melanoma
Ribas, Antoni
Flaherty, Keith T.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1865 - U11
[25] Fulminant type 1 diabetes mellitus caused by long-term nivolumab administration followed by nivolumab plus cabozantinib combination
Homma, Takamasa
Yoshida, Norio
Tanaka, Kuniaki
Isemura, Masaya
Torii, Shota
Kinoshita, Teruhisa
Esaki, Hideki
Sakakibara, Takashi
Takimoto, Norio
CHEMOTHERAPY, 2023, 68 (01) : 44 - 47
[26] Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy
Tauber, Marie
Cohen, Romain
Laly, Pauline
Josselin, Laurence
Andre, Thierry
Mekinian, Arsene
CLINICAL RHEUMATOLOGY, 2019, 38 (02) : 601 - 602
[27] Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy
Marie Tauber
Romain Cohen
Pauline Laly
Laurence Josselin
Thierry André
Arsène Mekinian
Clinical Rheumatology, 2019, 38 : 601 - 602
[28] Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
Antonia, S.
Gettinger, S.
Borghaei, H.
Goldman, J. W.
Brahmer, J.
Ready, N.
Gerber, D.
Chow, L.
Juergens, R.
Laurie, S.
Shepherd, F.
Li, X.
Li, A.
Geese, W.
Hellmann, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S458 - S458
[29] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
El-Khoueiry, Anthony B.
Yau, Thomas
Kang, Yoon-Koo
Kim, Tae-You
Santoro, Armando
Sangro, Bruno
Melero, Ignacio
Kudo, Masatoshi
Hou Ming-Mo
Matilla, Ana
Tovoli, Francesco
Knox, Jennifer J.
He, Aiwu Ruth
El-Rayes, Bassel F.
Acosta-Rivera, Mirelis
Lim, Ho Yeong
Memaj, Arteid
Sama, Ashwin Reddy
Hsu, Chiun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[30] Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma
Augustin, Ryan C.
Luke, Jason J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 443 - +

← 1 2 3 4 5 →